A Phase II, open-label, non-randomised multi-center study of the histone deacetylase inhibitor belinostat in combination with carboplatin and paclitaxel (BelCaP) for the treatment of patients with urothelial carcinoma of the bladder (transitional cell carcinoma, or TCC).

Trial Profile

A Phase II, open-label, non-randomised multi-center study of the histone deacetylase inhibitor belinostat in combination with carboplatin and paclitaxel (BelCaP) for the treatment of patients with urothelial carcinoma of the bladder (transitional cell carcinoma, or TCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2011

At a glance

  • Drugs Belinostat; Carboplatin; Paclitaxel
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2011 Status changed from not yet recruiting to completed, according to results presented at AACR-EORTC-NCI 2008.
    • 13 Sep 2011 Results reported in a TopoTarget media release, and will be presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology.
    • 22 Oct 2008 Results were presented at AACR-EORTC-NCI 2008 Conference, according to a TopoTarget media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top